Cargando…

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma

Resistance to chemotherapy is a major limitation of cancer treatments with several molecular mechanisms involved, in particular altered local drug metabolism and detoxification process. The role of drug metabolism and clearance system has not been satisfactorily investigated in Multiple Myeloma (MM)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hassen, Wafa, Kassambara, Alboukadel, Reme, Thierry, Sahota, Surinder, Seckinger, Anja, Vincent, Laure, Cartron, Guillaume, Moreaux, Jérôme, Hose, Dirk, Klein, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467447/ https://www.ncbi.nlm.nih.gov/pubmed/25669983

Ejemplares similares

A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy
por: Kassambara, Alboukadel, et al.
Publicado: (2014)

Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma
por: Kassambara, Alboukadel, et al.
Publicado: (2012)

Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells
por: Kassambara, Alboukadel, et al.
Publicado: (2013)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020)

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
por: Bruyer, Angelique, et al.
Publicado: (2018)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
por: Vikova, Veronika, et al.
Publicado: (2019)

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2021)

GenomicScape: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells
por: Kassambara, Alboukadel, et al.
Publicado: (2015)

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
por: Viziteu, Elena, et al.
Publicado: (2016)

An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy
por: Szablewski, Vanessa, et al.
Publicado: (2018)

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value
por: Viziteu, Elena, et al.
Publicado: (2016)

Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma
por: Cowan, Graeme, et al.
Publicado: (2015)

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
por: Alaterre, Elina, et al.
Publicado: (2017)

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays
por: Mahtouk, Karène, et al.
Publicado: (2010)

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression
por: Seckinger, Anja, et al.
Publicado: (2015)

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
por: Gourzones, Claire, et al.
Publicado: (2019)

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells
por: Lub, Susanne, et al.
Publicado: (2015)

Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact
por: Devin, Julie, et al.
Publicado: (2019)

Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell
por: Kassambara, Alboukadel, et al.
Publicado: (2017)

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
por: Wagner, Verena, et al.
Publicado: (2014)

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
por: Ovejero, Sara, et al.
Publicado: (2022)

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
por: Caraux, Anouk, et al.
Publicado: (2012)

Characterization of human FCRL4-positive B cells
por: Jourdan, Michel, et al.
Publicado: (2017)

The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation
por: Chatonnet, Fabrice, et al.
Publicado: (2020)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2015)

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
por: Hose, Dirk, et al.
Publicado: (2019)

EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015)

RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators
por: Kassambara, Alboukadel, et al.
Publicado: (2021)

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
por: Viziteu, E, et al.
Publicado: (2017)

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
por: Emde-Rajaratnam, Martina, et al.
Publicado: (2023)

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2022)

SULFs in human neoplasia: implication as progression and prognosis factors
por: Bret, Caroline, et al.
Publicado: (2011)

The Glycome of Normal and Malignant Plasma Cells
por: Moehler, Thomas M., et al.
Publicado: (2013)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells
por: Meißner, Tobias, et al.
Publicado: (2015)

Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
por: Herviou, Laurie, et al.
Publicado: (2021)

Differential effects of lenalidomide during plasma cell differentiation
por: Jourdan, Michel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_96gu7ehmfh7agi3rddql4q6p92